CONTEXT: Recovery of the hypothalamic-pituitary-adrenal axis (HPAA) after transsphenoidal surgery (TSS) for Cushing's disease (CD) in children has not been adequately studied. OBJECTIVE: Our objective was to assess time to recovery of the HPAA after TSS in children with CD. DESIGN AND SETTING: This was a case series at the National Institutes of Health Clinical Center. PATIENTS: Fifty-seven patients with CD (6-18 yr, mean 13.0 ± 3.1 yr) given a standard regimen of glucocorticoid tapering after TSS were studied out of a total of 73 recruited. INTERVENTIONS: ACTH (250 μg) stimulation tests were administered at approximately 6-month intervals for up to 36 months. Age, sex, pubertal status, body mass index, length of disease, midnight cortisol, and urinary free cortisol at diagnosis were analyzed for effects on recovery. MAIN OUTCOME MEASURE: The main outcome measure was complete recovery of the HPAA as defined by a cortisol level of at least 18 μg/dl in response to 250 μg ACTH. RESULTS: Full recovery was reached by 43 (75.4%) of 57 patients, with 29 of the 43 (67.4%) and 41 of the 43 (95.3%) recovering by 12 and 18 months, respectively. The overall mean time to recovery was 12.6 ± 3.3 months. Kaplan-Meier survivor function estimated a 50% chance of recovering by 12 months after TSS and 75% chance of recovering within 14 months. By receiver operating characteristic curve assessment, the cutoff of at least 10-11 μg/dl of cortisol as the peak of ACTH stimulation testing at 6 months after TSS yielded the highest sensitivity (70-80%) and specificity (64-73%) to predict full recovery of the HPAA at 12 months. Two of the four patients that recovered fully within 6 months had recurrent CD. CONCLUSIONS: Although this is not a randomized study, we present our standardized tapering regimen for glucocorticoid replacement after TSS that led to recovery of the HPAA in most patients within the first postoperative year. Multiple factors may affect this process, but an early recovery may indicate disease recurrence.
CONTEXT: Recovery of the hypothalamic-pituitary-adrenal axis (HPAA) after transsphenoidal surgery (TSS) for Cushing's disease (CD) in children has not been adequately studied. OBJECTIVE: Our objective was to assess time to recovery of the HPAA after TSS in children with CD. DESIGN AND SETTING: This was a case series at the National Institutes of Health Clinical Center. PATIENTS: Fifty-seven patients with CD (6-18 yr, mean 13.0 ± 3.1 yr) given a standard regimen of glucocorticoid tapering after TSS were studied out of a total of 73 recruited. INTERVENTIONS:ACTH (250 μg) stimulation tests were administered at approximately 6-month intervals for up to 36 months. Age, sex, pubertal status, body mass index, length of disease, midnight cortisol, and urinary free cortisol at diagnosis were analyzed for effects on recovery. MAIN OUTCOME MEASURE: The main outcome measure was complete recovery of the HPAA as defined by a cortisol level of at least 18 μg/dl in response to 250 μg ACTH. RESULTS: Full recovery was reached by 43 (75.4%) of 57 patients, with 29 of the 43 (67.4%) and 41 of the 43 (95.3%) recovering by 12 and 18 months, respectively. The overall mean time to recovery was 12.6 ± 3.3 months. Kaplan-Meier survivor function estimated a 50% chance of recovering by 12 months after TSS and 75% chance of recovering within 14 months. By receiver operating characteristic curve assessment, the cutoff of at least 10-11 μg/dl of cortisol as the peak of ACTH stimulation testing at 6 months after TSS yielded the highest sensitivity (70-80%) and specificity (64-73%) to predict full recovery of the HPAA at 12 months. Two of the four patients that recovered fully within 6 months had recurrent CD. CONCLUSIONS: Although this is not a randomized study, we present our standardized tapering regimen for glucocorticoid replacement after TSS that led to recovery of the HPAA in most patients within the first postoperative year. Multiple factors may affect this process, but an early recovery may indicate disease recurrence.
Authors: B Ambrosi; M Giovanelli; S M Gaini; D Bochicchio; E Riva; G Tomei; M Zavanone; G Faglia Journal: Acta Neurochir (Wien) Date: 1982 Impact factor: 2.216
Authors: Dalia L Batista; Edward H Oldfield; Margaret F Keil; Constantine A Stratakis Journal: J Clin Endocrinol Metab Date: 2009-05-26 Impact factor: 5.958
Authors: Alessandro Prete; Rosa Maria Paragliola; Filomena Bottiglieri; Carlo Antonio Rota; Alfredo Pontecorvi; Roberto Salvatori; Salvatore Maria Corsello Journal: Endocrine Date: 2016-07-09 Impact factor: 3.633
Authors: Luis G Perez-Rivas; Marily Theodoropoulou; Francesco Ferraù; Clara Nusser; Kohei Kawaguchi; Constantine A Stratakis; Fabio Rueda Faucz; Luiz E Wildemberg; Guillaume Assié; Rudi Beschorner; Christina Dimopoulou; Michael Buchfelder; Vera Popovic; Christina M Berr; Miklós Tóth; Arif Ibrahim Ardisasmita; Jürgen Honegger; Jerôme Bertherat; Monica R Gadelha; Felix Beuschlein; Günter Stalla; Masayuki Komada; Márta Korbonits; Martin Reincke Journal: J Clin Endocrinol Metab Date: 2015-05-05 Impact factor: 5.958
Authors: Evgenia Gourgari; Maya Lodish; Meg Keil; Robert Wesley; Suvimol Hill; Paraskevi Xekouki; Charalampos Lyssikatos; Elena Belyavskaya; Sierra Maria De La Luz; Constantine A Stratakis Journal: Endocr Relat Cancer Date: 2014-09-25 Impact factor: 5.678
Authors: Lynnette K Nieman; Beverly M K Biller; James W Findling; M Hassan Murad; John Newell-Price; Martin O Savage; Antoine Tabarin Journal: J Clin Endocrinol Metab Date: 2015-07-29 Impact factor: 5.958